The previous discussion centres around the use of HFRT; however, it is noteworthy that in the recently published phase 3 randomised PACIFIC trial31, the group that received consolidation therapy with the anti-PD-L1 antibody durvalumab following standard chemoradiation for locally advanced lung cancer had a much better PFS than the placebo group. The gene discussed is CD274; the disease is lung carcinoma.